The Role of Radiotherapy in Treating Kaposi's Sarcoma in HIV Infected Patients - Sorbonne Université
Journal Articles Cancers Year : 2022

The Role of Radiotherapy in Treating Kaposi's Sarcoma in HIV Infected Patients

Abstract

Kaposi's sarcoma (KS) is a radiosensitive cancer regardless of its form (classical, endemic, AIDS-related, and immunosuppressant therapy-related). Radiotherapy (RT) is an integral part of the therapeutic management of KS. RT may be used as the main treatment, in the case of solitary lesions, or as palliative therapy in the disseminated forms. The dose of RT to be delivered is 20\textendash 30 Gy by low-energy photons or by electrons. The complete response rate after RT is high, around 80\textendash 90%. This treatment is well tolerated. However, patients should be informed of the possible risk of the development of late skin sequelae and the possibility of recurrence. With the advent of highly active antiretroviral therapy (HAART), the indications for RT treatment in HIV-positive patients have decreased.

Dates and versions

hal-03793529 , version 1 (01-10-2022)

Identifiers

Cite

Laurent Quéro, Romain Palich, Marc-Antoine Valantin. The Role of Radiotherapy in Treating Kaposi's Sarcoma in HIV Infected Patients. Cancers, 2022, 14 (8), pp.1915. ⟨10.3390/cancers14081915⟩. ⟨hal-03793529⟩
28 View
0 Download

Altmetric

Share

More